- ISIN
- US61225M1027
- CUSIP
- 61225M102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 24, 2021
Highlights
- EPS (TTM)
- -$2.26
- Total Revenue (TTM)
- $42.95M
- Gross Profit (TTM)
- $34.56M
- EBITDA (TTM)
- -$139.25M
- Year Range
- $4.12 - $25.77
- Target Price
- $31.75
- ROA (TTM)
- -17.65%
- ROE (TTM)
- -24.91%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GLUE Performance Chart
Monte Rosa Therapeutics, Inc. (GLUE) is up 19.1% since the beginning of the year. At $19 per share, GLUE is trading 27.6% below its 52-week high of $26.
Loading charts...
Returns By Period
Monte Rosa Therapeutics, Inc. (GLUE) has returned 19.07% so far this year and 303.24% over the past 12 months.
Monte Rosa Therapeutics, Inc.
- 1D
- 1.97%
- 1M
- -0.74%
- YTD
- 19.07%
- 6M
- 15.32%
- 1Y
- 303.24%
- 3Y*
- 40.03%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
GLUE Monthly Returns History
Based on dividend-adjusted daily data since Jun 24, 2021, GLUE's average daily return is +0.17%, while the average monthly return is +2.88%. At this rate, an investment would double in approximately 2.0 years.
Historically, 46% of months were positive and 54% were negative. The best month was Dec 2023 with a return of +82.3%, while the worst month was Apr 2023 at -41.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.
On a daily basis, GLUE closed higher 48% of trading days. The best single day was Oct 28, 2024 with a return of +93.9%, while the worst single day was Jan 5, 2022 at -22.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.87% | -13.50% | -7.32% | 16.41% | 2.92% | -5.28% | 19.07% | ||||||
| 2025 | -4.03% | -17.42% | -15.64% | 5.82% | -14.87% | 7.89% | 9.76% | -3.03% | 54.37% | 73.41% | 25.84% | -3.03% | 125.94% |
| 2024 | -6.28% | 19.55% | 11.37% | -24.54% | -22.56% | -9.22% | 20.86% | 36.50% | -14.10% | 60.38% | 21.88% | -33.01% | 22.83% |
| 2023 | -2.76% | -17.84% | 28.12% | -41.72% | 62.56% | -7.18% | 3.21% | -16.97% | -18.40% | -29.02% | -8.82% | 82.26% | -25.76% |
| 2022 | -38.00% | 13.27% | -2.23% | -22.25% | -28.99% | 24.94% | -6.20% | -12.68% | 3.16% | 12.61% | -7.83% | -10.26% | -62.73% |
| 2021 | 3.18% | 8.02% | 45.55% | -37.57% | 5.25% | -17.31% | 5.31% | -7.18% |
Benchmark Metrics
Monte Rosa Therapeutics, Inc. has an annualized alpha of 24.97%, beta of 1.64, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since June 24, 2021.
- This stock captured 251.87% of S&P 500 Index gains and 215.75% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 24.97%
- Beta
- 1.64
- R²
- 0.08
- Upside Capture
- 251.87%
- Downside Capture
- 215.75%
Return for Risk
Risk / Return Rank
GLUE ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GLUE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.27 | ||
| Sortino ratioReturn per unit of downside risk | +1.63 | ||
| Omega ratioGain probability vs. loss probability | 1.50 | 1.37 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 7.30 | 2.78 | +4.52 |
| Martin ratioReturn relative to average drawdown | 15.20 | 12.44 | +2.76 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Monte Rosa Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Monte Rosa Therapeutics, Inc. was 94.08%, occurring on Oct 25, 2023. The portfolio has not yet recovered.
The current Monte Rosa Therapeutics, Inc. drawdown is 55.77%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -94.08%Oct 2023 | 2y 1mo | — | 4y 9moSep 2021 - now |
2021 correction2021 | -18.11%Jul 2021 | 12d | 10d | 22dJul 2021 - Jul 2021 |
2021 correction2021 | -14.27%Jun 2021 | 1d | 5d | 6dJun 2021 - Jun 2021 |
2021 pullback2021 | -7.83%Aug 2021 | 4d | 2d | 6dAug 2021 - Sep 2021 |
2021 pullback2021 | -4.70%Aug 2021 | 1d | 4d | 5dAug 2021 - Aug 2021 |
Drawdown Indicators
| GLUE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.08% | -56.78% | -37.30% |
Max Drawdown (1Y)Largest decline over 1 year | -41.84% | -9.10% | -32.74% |
Max Drawdown (3Y)Largest decline over 3 years | -65.37% | -18.90% | -46.47% |
Max Drawdown (5Y)Largest decline over 5 years | -94.08% | -25.43% | -68.65% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -55.77% | -1.80% | -53.97% |
Average DrawdownAverage peak-to-trough decline | -74.41% | -10.71% | -63.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.06% | 2.03% | +18.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Monte Rosa Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Monte Rosa Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GLUE relative to other companies in the Biotechnology industry. Currently, GLUE has a P/S ratio of 25.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GLUE
Add Monte Rosa Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GLUE